<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661437</url>
  </required_header>
  <id_info>
    <org_study_id>18140</org_study_id>
    <secondary_id>NCI-2018-01868</secondary_id>
    <secondary_id>18140</secondary_id>
    <nct_id>NCT03661437</nct_id>
  </id_info>
  <brief_title>Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy</brief_title>
  <official_title>Light Therapy to Prevent Frailty in Older Men With Prostate Cancer on Hormonal Therapy: A Pilot RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies how well systemic light exposure works in preventing frailty in&#xD;
      older patients with prostate cancer on hormonal therapy. Hormone therapy causes many symptoms&#xD;
      of frailty in older men including fatigue, slower time to walk a specified distance, reduced&#xD;
      activity levels, loss of lean muscle, and muscle weakness. It is not yet known if systemic&#xD;
      light exposure may reduce frailty in older prostate cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine if bright white light (BWL), compared to dim white light (DWL), significantly&#xD;
      prevents frailty development in older prostate cancer (PC) patients following prostate&#xD;
      anti-androgen therapy initiation.&#xD;
&#xD;
      II. Determine if BWL, compared to DWL, significantly increases functional performance and&#xD;
      physical activity levels, yields significant reductions in fatigue, lowers body mass index&#xD;
      (BMI), and reduces weakness in older PC patients following prostate anti-androgen therapy&#xD;
      initiation.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. Examine the feasibility of collecting and storing clinically-usable bio-measures for&#xD;
      future analysis in patients at baseline and if available at 6 months, including blood samples&#xD;
      (inflammatory markers), and salivary swabs (genetics, genomics, cortisol circadian rhythms).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I (BWL): Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months.&#xD;
      Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using&#xD;
      Luminette glasses for 30 minutes every morning for 3-6 months.&#xD;
&#xD;
      ARM II (DWL): Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months.&#xD;
      Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using&#xD;
      Luminette glasses for 30 minutes every morning for 3-6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">April 14, 2022</completion_date>
  <primary_completion_date type="Actual">July 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical performance in older prostate cancer (PC) patients following prostate anti-androgen therapies initiation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be assessed using Short Physical Performance Battery (SPPB). Will be evaluated using a repeated measures mixed linear model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frailty development in older PC patients following prostate anti-androgen therapies initiation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be assessed using SPPB. Will be evaluated using a repeated measures mixed linear model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue level</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be measured using the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue. Will be evaluated using a repeated measures mixed linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical performance</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be assessed by measuring the waist and hip circumference using a fabric measuring tape to determine the circumference of the waist (centered at the umbilicus) and hip (centered on the greater trochanter). Will be evaluated using a repeated measures mixed linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand-grip strength measured using hand-held dynamometer</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Muscle weakness will be measured by grip strength. Will be evaluated using a repeated measures mixed linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental activities of daily living (IADL) scale</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will be evaluated using a repeated measures mixed linear model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity level</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Activity counts will be recorded with the Actiwatch Spectrum Plus for five days at each time-point. Will be evaluated using a repeated measures mixed linear model.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Collecting and storing clinically-usable bio-measures</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>Blood samples and saliva swaps will be collected for future analysis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (BWL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (DWL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Actigraph</intervention_name>
    <description>Wear Actiwatch</description>
    <arm_group_label>Arm I (BWL)</arm_group_label>
    <arm_group_label>Arm II (DWL)</arm_group_label>
    <other_name>Actigram</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (BWL)</arm_group_label>
    <arm_group_label>Arm II (DWL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systematic Light Exposure</intervention_name>
    <description>Undergo BWL treatment</description>
    <arm_group_label>Arm I (BWL)</arm_group_label>
    <other_name>sLE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systematic Light Exposure</intervention_name>
    <description>Receive DWL treatment</description>
    <arm_group_label>Arm II (DWL)</arm_group_label>
    <other_name>sLE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prostate cancer (PC) patients who are starting androgen deprivation therapy (ADT),&#xD;
             abiraterone, or enzalutamide with plans to continue for at least six months with&#xD;
             minimal evidence of disease burden in accordance with current standards of care.&#xD;
&#xD;
          -  A life expectancy of 6 months or longer.&#xD;
&#xD;
          -  All subjects must have the ability to understand and the willingness to sign a written&#xD;
             or electronic informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant pre-existing frailty precluding completion of baseline assessments.&#xD;
&#xD;
          -  Other active malignancies&#xD;
&#xD;
          -  Previous use of radiation therapy within the year prior to consent.&#xD;
&#xD;
          -  Widely metastatic disease.&#xD;
&#xD;
          -  Confounding serious medical illnesses which causes frailty.&#xD;
&#xD;
          -  Severe sleep disorders.&#xD;
&#xD;
          -  Eye diseases which limit the ability of light to be processed.&#xD;
&#xD;
          -  Severe psychological impairment.&#xD;
&#xD;
          -  Current employment in night shift work.&#xD;
&#xD;
          -  Previous use of light therapy to alleviate fatigue or depressive symptoms.&#xD;
&#xD;
          -  Secondary cancer diagnosis within the past 5 years.&#xD;
&#xD;
          -  Plans to travel across meridians during treatment.&#xD;
&#xD;
          -  Uncontrolled illness including ongoing or active infection in disease status patients.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Dale</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

